Jeff Fischer is Co-Founder and President of Longhorn Vaccines and Diagnostics — a commercial diagnostics company also developing monoclonal antibodies that target chronic inflammation at its source. Most biologics turn off cytokines downstream. His approach goes upstream — removing the bacterial trigger that turns on inflammation in the first place.
Steve Butts is Co-Founder and CEO of Arrivo BioVentures, based in Research Triangle Park, NC. 20 years of biotech startups. His lead asset is a SIRT6 activator for major depression. In their Phase 2 study, it worked remarkably well in women — and not at all in men. Then came the question from investors: “Is there really a market for a depression drug that only works in females?”
In Today’s Episode We Discuss:
- Longevity Isn’t Living to 120 — It’s Expanding Healthspan
- We’re in the Early Stages: Prevention Over Cure
- SIRT6: DNA Repair, Mitochondrial Health, Glucose Metabolism, Inflammation
- Chronic Inflammation: The Upstream Trigger Most Biologics Ignore
- Bacterial Translocation: When Gut Bacteria Leak Into the Bloodstream
- Estrogen, Gut Junctions, and Why Menopause Changes Everything
- Depressed Men and Women Express the Same Genes in Opposite Directions
- The Depression Drug That Only Works in Females
- “Is There Really a Market for a Drug That Only Works in Women?”
- Educating Investors on Sex-Based Medicine
- More Data Earlier: What Novel Mechanisms Require
- Longevity for the Few vs. Longevity for the Many
- GLP-1s Are Tightening Gut Junctions — That’s Why They Work
- Gut Health and Cancer Survivors
- Tremendous Capital Is Now Pouring Into Longevity
Need the life-sciences signal but short on time?
Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.
